Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata

    January 2022 in “ PubMed ”
    Aditya K. Gupta, Tong Wang, Kimberly Vincent, William Abramovits
    Studysummary This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Related research 8

    1. Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata Dermatology Reports · 2022
    2. Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata Dermatology Reports · 2021
    3. Topical Tofacitinib in Treatment of Alopecia Areata Einstein (São Paulo) · 2020
    4. Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis 프로그램북(구 초록집) · 2019
    5. Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature JAAD Case Reports · 2018
    6. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    7. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    8. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016